Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
Fecal Microbiota(Mayo Clinic) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
Fecal Microbiota(Mayo Clinic): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Cardiotrophin-1(Biotecnol Ltd.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
Cardiotrophin-1(Biotecnol Ltd.): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
CAR-T-19(Immunotech Biopharm) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
CAR-T-19(Immunotech Biopharm): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
HIV DNA vaccine(GENEART AG) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
HIV DNA vaccine(GENEART AG): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Danzhi Qing'e tablets Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
Danzhi Qing'e tablets: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
BG505 MD39.3 gp151 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
BG505 MD39.3 gp151: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
RAY-121 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
RAY-121: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
SXC-2023 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
SXC-2023: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
BA-1301 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
BA-1301: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
CDR-404 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
CDR-404: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ASKG-915 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
ASKG-915: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
NT-219 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
1 September 2026
NT-219: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.